×
A call to caution when hydroxychloroquine is given to elderly COVID-19 patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035801
International Journal of Infectious Diseases : IJID : Off... Gabor JJ, Kreidenweiss A et. al.

Apr 13th, 2021 - Hydroxychloroquine use in COVID-19 patients was widespread and uncontrolled until recently. Patients vulnerable to severe COVID-19 are at risk for hydroxychloroquine interactions with comorbidities and co-medications contributing to detrimental, including fatal adverse treatment effects. This is a retrospective survey of health conditions and co-medications of COVID-19 patients who were pre-scr...

Prevalence of COVID-19 and Seroprevalence to SARS-CoV-2 in a Rheumatologic Patients Pop...
https://doi.org/10.1111/imj.15202
Internal Medicine Journal; Eviatar T, Elalouf O et. al.

Apr 12th, 2021 - to investigate prevalence of COVID-19 cases and seroprevalence among rheumatologic patients and the risk factors for infection. a cross sectional study in a rheumatologic population .An online questionnaire was sent on 31st April 2020. Blood Samples from 20% sample of patients were drawn for SARS-CoV-2 antibodies. Patients were divided based on autoimmune (AI) diagnosis. Prevalence of COVID-19 ...

Assessment and management of asymptomatic COVID-19 infection: A Systematic Review.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025627
Travel Medicine and Infectious Disease; Barboza JJ, Chambergo-Michilot D et. al.

Apr 10th, 2021 - COVID-19 can be asymptomatic in a substantial proportion of patients. The assessment and management of these patients constitute a key element to stop dissemination. To describe the assessment and treatment of asymptomatic infection in patients with a confirmed diagnosis of COVID-19. We searched five databases and search engines for preprints/preproofs, up to August 22, 2020. We included cohort...

Safety of treatment with chloroquine and hydroxychloroquine: A ten-year systematic revi...
https://doi.org/10.1016/j.ejim.2021.03.028
European Journal of Internal Medicine; Edington FLB, Gadellha SR et. al.

Apr 9th, 2021 - To estimate the incidence rate ratio (IRR) of adverse events (AE) in chloroquine or hydroxychloroquine users. We systematically reviewed randomized controlled trials (RCTs), using MEDLINE (2010-2020) and EMBASE (2010-2020) databases, reporting AE in chloroquine or hydroxychloroquine users during treatment for lupus, rheumatoid arthritis, malaria and COVID-19. The protocol for this systematic re...

What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ...
https://doi.org/10.1177/1120672120958323
European Journal of Ophthalmology; Fambuena-Muedra I, Jiménez-García M et. al.

Apr 8th, 2021 - Within the COVID-19 pandemic context, the WHO has proposed a list of medicines to treat patients with severe acute respiratory syndrome (SARS-CoV-2). An analysis of their ocular side effects was performed. Only chloroquine and hydroxychloroquine were found to have an ocular impact in the medium and long-term. Detailed search strategies were performed in EMBASE, MEDLINE, SCOPUS and WOS Core Coll...

Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic dis...
https://doi.org/10.1371/journal.pone.0249036
PloS One; Macías J, González-Moreno P et. al.

Apr 8th, 2021 - Hydroxychloroquine is not efficacious as post-exposure prophylaxis against coronavirus disease 2019 (COVID-19). It is not known whether as pre-exposure prophylaxis it may prevent COVID-19. To compare the incidence of COVID-19 in Spanish patients with autoimmune rheumatic diseases treated with and without hydroxychloroquine. Retrospective electronic record review, from February 27th to June 21st...

Daily briefing: The evidence is not stacking up for hydroxychloroquine as a treatment f...
https://doi.org/10.1038/d41586-020-01053-w
Nature Graham F, Castelvecchi D et. al.

Apr 7th, 2021 - Daily briefing: The evidence is not stacking up for hydroxychloroquine as a treatment for COVID-19.|2021|Graham F,Castelvecchi D,Phillips N,|

Drugs intervention study in COVID-19 management.
https://doi.org/10.1515/dmdi-2020-0173
Drug Metabolism and Personalized Therapy; Taher M, Tik N et. al.

Apr 5th, 2021 - By 9 February 2021, the Coronavirus has killed 2,336,650 people worldwide and it has been predicted that this number continues to increase in year 2021. The study aimed to identify therapeutic approaches and drugs that can potentially be used as interventions in Coronavirus 2019 (COVID-19) management. A systematic scoping review was conducted. Articles reporting clinical evidence of therapeutic...

Obesity is a Major Risk Factor for Hospitalization in Community-Managed COVID-19 Pneumo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859712
Mayo Clinic Proceedings; Cottini M, Lombardi C et. al.

Apr 5th, 2021 - We aimed to investigate whether the stratification of outpatients with coronavirus disease 2019 (COVID-19) pneumonia by body mass index (BMI) can help predict hospitalization and other severe outcomes. We prospectively collected consecutive cases of community-managed COVID-19 pneumonia from March 1 to April 20, 2020, in the province of Bergamo and evaluated the association of overweight (25 kg/...

Hydroxychloroquine in mild-to-moderate COVID-19: a placebo-controlled double blind trial.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015393
Clinical Microbiology and Infection : the Official Public... Dubée V, Roy PM et. al.

Apr 4th, 2021 - To determine whether hydroxychloroquine decreases the risk of adverse outcome in patients with mild-to-moderate COVID-19 at high risk of worsening. We conducted a multicentre randomized double-blind placebo-controlled trial evaluating hydroxychloroquine in COVID-19 patients with at least one of the following risk factors for worsening: need for supplemental oxygen, age ≥75 years, age between 60...

How does COVID-19 impact psoriasis practice, prescription patterns, and healthcare deli...
https://doi.org/10.1111/jocd.14104
Journal of Cosmetic Dermatology; El-Komy MHM, Abdelnaby A et. al.

Apr 3rd, 2021 - Psoriasis is a chronic skin disease that needs continuous medical care. During COVID-19, delivering medical service was negatively affected. To describe the impact of COVID-19 on psoriasis healthcare delivery, management, and practice. This observational cross-sectional study was conducted on 197 dermatologists using a validated online questionnaire. The survey evaluated the effect of COVID-19 ...

Adverse Drug Event Risk Assessment by the Virtual Addition of COVID-19 Repurposed Drugs...
https://doi.org/10.1111/cts.13025
Clinical and Translational Science; Smith MK, Bikmetov R et. al.

Mar 31st, 2021 - Drug safety is generally established from clinical trials, by pharmacovigilance programs and during observational Phase IV safety studies according to drug intended or approved indications. The objective of this study was to estimate the risk of potential adverse drug events (ADE) associated with drugs repurposed for COVID-19 treatment in a large-scale population. Drug claims were used to calcu...

DMARD Changes for Patients with Rheumatoid Arthritis in the US During the COVID-19 Pand...
https://doi.org/10.1002/acr.24611
Arthritis Care & Research; Michaud K, Pedro S et. al.

Mar 31st, 2021 - To understand medication, lifestyle, and clinical care changes by persons with RA during the first months (March through May 2020) of the COVID-19 pandemic in the US. Data were provided by adults with RA participating in FORWARD, The National Databank for Rheumatic Diseases, observational registry who answered COVID-19 web-based surveys in May 2020 and previously provided baseline (pre-COVID) c...

The effects of combination of Zingiber officinale and Echinacea on alleviation of clini...
https://doi.org/10.1515/jcim-2020-0283
Journal of Complementary & Integrative Medicine; Mesri M, Esmaeili Saber SS et. al.

Mar 31st, 2021 - Herbal medicines, as a treatment method, have received a great deal of attention. The effects of two herbal medicines namely Zingiber officinale and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19 outpatients were examined. A clinical trial with 100 suspected COVID-19 outpatients as participants was conducted. The participants were allocated randomly...

Publication by association: how the COVID-19 pandemic has shown relationships between a...
https://doi.org/10.1136/bmjebm-2021-111670
BMJ Evidence-based Medicine; Locher C, Moher D et. al.

Mar 31st, 2021 - During the COVID-19 pandemic, the rush to scientific and political judgements on the merits of hydroxychloroquine was fuelled by dubious papers which may have been published because the authors were not independent from the practices of the journals in which they appeared. This example leads us to consider a new type of illegitimate publishing entity, 'self-promotion journals' which could be de...

In Vitro Safety "Clinical Trial" of the Cardiac Liability of Drug Polytherapy.
https://doi.org/10.1111/cts.13038
Clinical and Translational Science; Charrez B, Charwat V et. al.

Mar 31st, 2021 - Only a handful of FDA Emergency Use Authorizations exist for drug and biologic therapeutics that treat SARS-CoV-2 infection. Potential therapeutics include repurposed drugs, some with cardiac liabilities. We report on a chronic preclinical drug screening platform, a cardiac microphysiological system (MPS), to assess cardiotoxicity associated with repurposed hydroxychloroquine (HCQ) and azithrom...

Coronavirus disease 2019 (COVID-19) and QTc prolongation.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007653
BMC Cardiovascular Disorders; Changal K, Paternite D et. al.

Mar 31st, 2021 - The cause-and-effect relationship of QTc prolongation in Coronavirus disease 2019 (COVID-19) patients has not been studied well. We attempt to better understand the relationship of QTc prolongation in COVID-19 patients in this study. This is a retrospective, hospital-based, observational study. All patients with normal baseline QTc interval who were hospitalized with the diagnosis of COVID-19 i...

System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in ...
https://doi.org/10.1080/14787210.2021.1909476
Expert Review of Anti-infective Therapy; Kumar-M P, Mohindra R et. al.

Mar 30th, 2021 - Hydroxychloroquine (HCQ) was one of the earliest drugs to be recommended for tackling the COVID-19 threat leading to its widespread usage across the world. We provide preliminary findings of the system, established in a tertiary care academic centre for the administration of HCQ prophylaxis to healthcare workers (HCW) based on Indian Council of Medical Research (ICMR) advisory. A dedicated clin...

A metaresearch study revealed susceptibility of Covid-19 treatment research to white ha...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997163
Journal of Clinical Epidemiology; Bellos I

Mar 29th, 2021 - To investigate the presence of white hat bias in Covid-19 treatment research by evaluating the effects of citation and reporting bias. Citation bias was investigated by assessing the degree of agreement between evidence provided by a remdesivir randomized controlled trial and its citing articles. The dissimilarity of outcomes derived from nonrandomized and randomized studies was tested by a met...

Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342085
American Journal of Otolaryngology; De Luca P, Scarpa A et. al.

Mar 29th, 2021 - Current clinical evidences do not support any specific treatment against SARS-CoV-2. Chloroquine (CQ) and hydroxychloroquine (HCQ) are typically used in the treatment of rheumatoid arthritis, systemic lupus erythematosus and malaria; they have been considered for off-label and compassionate use in several countries against moderate to severe cases of COVID-19 and there's actually a massive dema...